Treatment of Systemic Mast-Cell Disease with Cladribine

Authors:
  • ATAyalew Tefferi
    Ayalew Tefferi
  • CLChin-Yang Li
    Chin-Yang Li
  • JBJoseph H. Butterfield
    Joseph H. Butterfield
  • HHH. Clark Hoagland
    H. Clark Hoagland

Abstract
Cladribine (2-chlorodeoxyadenosine) is a purine nucleoside analogue with activity against various hematologic cancers.1 Because mast cells are derived from hematopoietic stem cells,2 we evaluated the therapeutic activity of cladribine in a patient with interferon alfa–resistant systemic mast-cell disease.